TX-SOFTSERVE
5.5.2022 15:07:09 CEST | Business Wire | Press release
SoftServe , a leading digital authority and consulting company, has opened delivery offices in Guadalajara, Mexico and Medellín, Colombia as part of its strategy to extend global delivery capabilities to Latin America. SoftServe now has 30 delivery center locations globally, Guadalajara and Medellín are the first in Latin America. The company’s plans to expand also include opening another delivery office in Chile.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220505005015/en/
“As our client roster continues to grow, both new and existing customers are requesting more digital engineering to support their transformations,” said Chris Baker, Chief Executive Officer at SoftServe. “Delivery offices in Latin America will better connect our clients to top talent in the region and will more efficiently support operations within these time zones. SoftServe maintains a long-term strategy to expand a truly global footprint of delivery centers, and we are thrilled about this next step into Latin America.”
With over 500,000 IT professionals in software engineering and 350,000 IT graduates, annually, throughout Mexico, Colombia, and Chile, and given the geographical proximity to the United States, Latin America is an attractive destination for the global delivery operations of major technology players. Opening this vibrant new talent region will support SoftServe’s growth and will help accelerate the execution of its global delivery expansion.
“We are planning to welcome more than 3,000 local people in this region to our global team by 2025,” said Keith Rozmus, North America Division President at SoftServe. “Our presence in Latin America will allow us to bring value to our North American clients by offering 24/7 nearshoring and offshoring options with minimum time shifts. We will also create new opportunities investing in local communities and building learning and re-skilling capabilities for local talent.”
SoftServe aims to bring its best practices and benefits to employees in Latin America. The company will offer associates highly competitive learning solutions powered by SoftServe University , professional certifications, and international assignments. People Excellence , SoftServe’s proprietary professional development platform, will help accelerate career development by tracking achievements and providing a roadmap for gaining new expertise. Meaningful project assignments and a great work environment are highly influential factors for productivity and happiness, and with the current 84 Employee Net Promoter Score, SoftServe will aim to become an employer of choice in Latin America. The company will also give back to local communities by empowering its people to engage in social responsibility activities, including Open Eyes charities and Open/Tech pro bono technology initiatives.
To learn more about SoftServe’s presence in Latin America, please visit the company’s website .
About SoftServe
Employing more than 13,000 associates in 41 centers, offices, and client locations globally, SoftServe has a proven track record in healthcare and life sciences, financial services and insurance, retail, high-tech (ISVs), manufacturing and energy industries. The company offers deep expertise across software engineering, cloud and DevOps, big data and analytics, AI and machine learning, the Internet of Things, experience design and platforms, extended reality (XR) and robotics.
SoftServe delivers open innovation—from generating compelling new ideas, to developing and implementing transformational products and services. Our work and client experience are built on a foundation of empathetic, human-focused experience design that ensures continuity from concept to release. We empower enterprises and software companies to (re)identify differentiation, accelerate solution development, and vigorously compete in today’s digital economy.
Visit our website , blog , LinkedIn , Facebook , and Twitter pages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005015/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom